Prochlorperazine

May be taken with or without food.

Reye's syndrome, comatose patients. Children <2 years or weighing <9 kg.

Patient with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problems, stroke, cerebrovascular disease, severe CV disease, dementia, Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis, prostate hyperthrophy. hypovolaemia, epilepsy or history risk of seizures. Children and elderly. Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery. Avoid exposure to extreme heat. Monitoring Parameters Monitor for electrolytes, CBC, LFT, fasting plasma glucose level, lipid panel, visual changes. Discontinue treatment if neutrophil count is <1,000/mm³. Monitor for changes in mental status, vital signs, weight, BMI, waist circumference, tardive dyskinesia, changes in menstruation, libido, development of galatorrhoea, erectile and ejaculatory function, fever, muscle rigidity, autonomic instability.

Significant: Cholinergic effects (e.g. constipation, xerostomia, blurred vision, urinary retention), aspiration of vomit, extrapyramidal symptoms, somnolence, orthostatic hypotension, motor instability, hyperprolactinemia, pigmentary retinopathy, lenticular or corneal deposits, impaired body temperature regulation. Endocrine disorders: Amenorrhoea. Gastrointestinal disorders: Nausea, obstipation, intestinal obstruction, vomiting. Hepatobiliary disorders: Jaundice. Immune system disorders: Angioedema, urticaria. Metabolism and nutrition disorders: Hyponatraemia, hyperglycaemia. Nervous system disorders:Acute dystonia, dyskinesia, parkinsonism, tardive dyskinesia, agitation, convulsion. Psychiatric disorder: Akathisia, insomnia. Renal and urinary disorders: Urinary retention. Reproductive system and breast disorder: Impotence, ejaculatory disorder. Respiratory, thoracic and mediastinal disorders: Respiratory depression. Skin and subcutaneous tissue disorders: Contact dermatitis, rash.
Potentially Fatal: Arrhythmias, torsade de pointes, blood dyscrasias (e.g. leucopenia, neutropenia, agranulocytosis), hypotension, neuroleptic malignant syndrome (e.g. hyperpyrexia, muscle rigidity, altered mental status).

Enhanced CNS depression with barbiturates and sedatives. Reduced antipsychotic effect with anticholinergics. May reduce the effect of hypoglycaemic agents. Increased risk of arrhythmias with antidepressants. Increased risk of agranulocytosis with carbamazepine. Increased neurotoxicity with lithium. Diminished therapeutic effect of oral anticoagulant. Decreased absorption with antacids.

Antipsychotics / Antivertigo Drugs

N05AB04 - prochlorperazine ; Belongs to the class of phenothiazine antipsychotics with piperazine structure.